1 – 20 of 20
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit
(
- Contribution to journal › Article
- 2023
-
Mark
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer : data from the randomized SBII:2 trial
(
- Contribution to journal › Article
-
Mark
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
(
- Contribution to journal › Article
- 2022
-
Mark
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
(
- Contribution to journal › Article
- 2020
-
Mark
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer : data from a randomised trial with long-term follow-up
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
(
- Contribution to journal › Article
- 2016
-
Mark
Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer : Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
(
- Contribution to journal › Article
- 2014
-
Mark
Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
(
- Contribution to journal › Article
- 2013
-
Mark
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
(
- Contribution to journal › Article
- 2010
-
Mark
17 beta-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer
(
- Contribution to journal › Article
- 2009
-
Mark
Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
(
- Contribution to journal › Article
- 2008
-
Mark
Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
(
- Contribution to journal › Article
-
Mark
Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
(
- Contribution to journal › Article
-
Mark
Exploring the two-gene ratio in breast cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome
(
- Contribution to journal › Article
- 2006
-
Mark
Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
(
- Contribution to journal › Article
-
Mark
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
(
- Contribution to journal › Article
- 2005
-
Mark
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
(
- Contribution to journal › Article
- 2002
-
Mark
Swedish Cancer Society radiation therapy research investigation.
(
- Contribution to journal › Article